Learn about the latest advancements in immunotherapy research focusing on harnessing IL-12 for the treatment of ovarian cancer to potentially improve survival rates.

Discover how targeted therapies are revolutionizing autoimmune disease treatment by offering greater precision.

During a live event, Christine Bestvina, MD, reviewed outcomes from the phase 3 KRYSTAL-12 and CodeBreak 200 trials in the ...

ACROBiosystems is breaking the chain of chronic suffering and safeguarding intestinal health. Learn how in this article.

Belzutifan is a hypoxia-inducible factor-2α inhibitor that is US FDA approved for the treatment of VHL disease-associated renal cell carcinoma (RCC), CNS hemangioblastomas, or pancreatic ...

Benign and cancerous calcium phosphate deposits that may look identical on a mammogram have distinct differences in their ...

Three Democratic-led states that offered free health care to low-income people who are in the U.S. without legal permission ...

Benign and cancerous calcium phosphate deposits that may look identical on a mammogram have distinct differences in their structures and formation processes, researchers at the University of Illinois ...

A new immunotherapy trial to treat the deadliest form of brain cancer is seeking patients after one man had remarkable results that saw his tumour vanish. The NHS study will recruit 16 people over an ...

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 ...

Icotrokinra is currently being developed through a licensing and collaboration agreement between Protagonist and J&J.